ArticleiMetaOmics2026
Probiotics-derived postbiotics improve host metabolic syndrome by activating the adipocyte thermogenic signaling pathway in high-fat diet-fed mice.
Article in iMetaOmics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic syndrome, including type 2 diabetes mellitus (T2DM) and obesity, represents a global health challenge. While probiotics can modulate host metabolism, postbiotics (inanimate microbial preparations) have emerged as potentially safer and more stable therapeutic alternatives. The current study investigates the effects of postbiotics derived from five human-origin bacterial strains in mice model with high-fat diet-induced metabolic syndrome. Using multi-omics profiling, we demonstrate that supplementation of postbiotics significantly ameliorates weight gain, improves glucose tolerance and insulin sensitivity, and alleviates hepatic steatosis. Transcriptomic analysis indicates that the treatment upregulated adipocyte genes related to thermogenesis and fatty acid oxidation while downregulating hepatic lipid synthesis. Most importantly, the intervention reshapes the gut microbiota structure. Target metabolomics reveals that this microbial remodeling is accompanied by a significant elevation of indole-3-acetic acid (IAA), a tryptophan-derived microbial metabolite, in the host serum. Functional studies in primary adipocytes confirm that IAA is sufficient to trigger thermogenic gene expression and activate AMP-activated protein kinase (AMPK) signaling. These findings suggest a mechanism where postbiotics improve metabolic health by modulating the gut ecosystem to enrich beneficial metabolites like IAA, which in turn ameliorates the metabolic syndrome and promotes adipocyte thermogenesis and lipolysis. The present research supports postbiotics as a promising therapeutic strategy for metabolic syndrome and highlights the importance of the gut microbiota-metabolite axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.